

PDL BIOPHARMA, INC.  
Form 8-K  
July 31, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (date of earliest event reported):**

**July 30, 2009**

**PDL BioPharma, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction

of incorporation)

**000-19756**  
(Commission File No.)

**932 Southwood Boulevard**

**94-3023969**  
(I.R.S. Employer

Identification No.)

Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

**Incline Village, Nevada 89451**

(Address of principal executive offices)

**Registrant's telephone number, including area code:**

**(775) 832-8500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition.**

On July 30, 2009, PDL BioPharma, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2009 (the Earnings Release ). The Earnings Release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release, dated July 30, 2009, regarding the financial results of PDL BioPharma, Inc. for the second quarter ended June 30, 2009.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 30, 2009

**PDL BioPharma, Inc.**

By: /s/ Christine R. Larson  
Christine R. Larson  
Vice President and Chief Financial Officer

EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release, dated July 30, 2009, regarding the financial results of PDL BioPharma, Inc. for the second quarter ended June 30, 2009.